Cargando…
Castration-resistant prostate cancer: systemic therapy in 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease with prostatectomy and radiation therapy, som...
Autores principales: | Maluf, Fernando C., Smaletz, Oren, Herchenhorn, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317249/ https://www.ncbi.nlm.nih.gov/pubmed/22522765 http://dx.doi.org/10.6061/clinics/2012(04)13 |
Ejemplares similares
-
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019) -
Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012) -
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
por: Hatano, Koji, et al.
Publicado: (2023) -
Impact of Pathology Review for Decision Therapy in Localized Prostate Cancer
por: Usón, Pedro Luiz Serrano, et al.
Publicado: (2017) -
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
por: Liu, Hsin-Ho, et al.
Publicado: (2014)